Press Releases

All Releases
View Summary Ironwood Pharmaceuticals to Host R&D Day on March 9, 2017
Feb 23, 2017
PDF 13.7 KB Add to Briefcase
View Summary Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2016 Investor Update
Feb 21, 2017
PDF 144.5 KB Add to Briefcase
View Summary Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2016 Investor Update Call
Feb 7, 2017
PDF 13.0 KB Add to Briefcase
View Summary Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Constipation Conducted in Japan
Jan 29, 2017
PDF 291.9 KB Add to Briefcase
View Summary U.S. Food and Drug Administration Approves 72 mcg Dose of LINZESS® (linaclotide) for Adults with Chronic Idiopathic Constipation
Jan 26, 2017
PDF 332.0 KB Add to Briefcase
View Summary Ironwood Pharmaceuticals Demonstrates Strong Execution on Strategy to Build Top-Performing Commercial Biotech
Jan 8, 2017
PDF 387.3 KB Add to Briefcase
View Summary Ironwood Pharmaceuticals Appoints Amy Schulman to Board of Directors
Jan 4, 2017
PDF 15.5 KB Add to Briefcase
View Summary Ironwood Announces New Drug Application for DUZALLO™ (Fixed-Dose Combination of Lesinurad and Allopurinol) Has Been Accepted for FDA Review
Jan 4, 2017
PDF 289.6 KB Add to Briefcase
View Summary Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
Jan 3, 2017
PDF 12.8 KB Add to Briefcase
View Summary Ironwood and Allergan Report Topline Phase IIb Data Supporting Advancement of Linaclotide Colonic Release-1 (CR1) in IBS-C
Dec 22, 2016
PDF 343.7 KB Add to Briefcase
View Summary Ironwood and Allergan Report Topline Phase IIb Data Supporting Further Investigation of Linaclotide Colonic Release-2 (CR2) for Abdominal Pain in Non-Constipation Subtypes of IBS
Dec 22, 2016
PDF 294.4 KB Add to Briefcase
View Summary Ironwood Pharmaceuticals Announces Approval of LINZESS® (linaclotide) in Japan for the Treatment of Adults with IBS-C
Dec 19, 2016
PDF 333.5 KB Add to Briefcase
View Summary Ironwood Highlights ZURAMPIC® (lesinurad) Phase III Extension Study Data at the American College of Rheumatology 2016 Annual Meeting
Nov 13, 2016
PDF 23.5 KB Add to Briefcase
View Summary Ironwood Pharmaceuticals to Present at Stifel 2016 Healthcare Conference
Nov 10, 2016
PDF 12.6 KB Add to Briefcase
View Summary Ironwood Pharmaceuticals Provides Third Quarter 2016 Investor Update
Nov 3, 2016
PDF 103.9 KB Add to Briefcase
View Summary Ironwood Pharmaceuticals to Present at Credit Suisse 25th Annual Healthcare Conference
Nov 1, 2016
PDF 12.7 KB Add to Briefcase
View Summary Ironwood Highlights Breadth of Gout Research with Presentations at the American College of Rheumatology 2016 Annual Meeting
Oct 25, 2016
PDF 26.7 KB Add to Briefcase
View Summary Ironwood Pharmaceuticals to Host Third Quarter 2016 Investor Update Call
Oct 20, 2016
PDF 13.0 KB Add to Briefcase
View Summary Nine in Ten Physicians Agree Target Goal for Gout Is Imperative, Yet Half of Patients Fail to Reach It, New Survey Shows
Oct 3, 2016
PDF 17.0 KB Add to Briefcase
View Summary Ironwood Announces U.S. Availability of ZURAMPIC® (lesinurad) 200 mg Tablets for Patients with Uncontrolled Gout
Oct 3, 2016
PDF 77.6 KB Add to Briefcase
Showing 1-20 of 225 Page: 1 2 3 4 5 ... 12  Next 20
Add to Briefcase = add release to Briefcase
You are now leaving ironwoodpharma.com. This link will take you to
a website to which our privacy policy does not apply. You are solely
responsible for your interactions with that website.